trending Market Intelligence /marketintelligence/en/news-insights/trending/gnin1ernlqmtoebcxnf-yq2 content esgSubNav
In This List

TherapeuticsMD medicine secures US FDA approval to treat vaginal pain

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


TherapeuticsMD medicine secures US FDA approval to treat vaginal pain

TherapeuticsMD Inc. said the U.S. Food and Drug Administration approved its medicine Imvexxy to treat moderate to severe dyspareunia, or vaginal pain associated with sexual activity.

The condition is a symptom of vulvar and vaginal degeneration, which affects an estimated 32 million postmenopausal women in the U.S., the Boca Raton, Fla.-based women's healthcare products company said in a statement.

Imvexxy will be available for commercial distribution in July.

As part of the FDA's approval, TherapeuticsMD has agreed to conduct a post-approval observational study.